Activate Now
ProHealth me-cfs Vitamin and Natural Supplement Store and Health
Home  |  Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help
Facebook Google Plus
Fibromyalgia  Chronic Fatigue Syndrome & M.E.  Lyme Disease  Natural Wellness  Supplement News  Forums  Our Story
Store     Brands   |   A-Z Index   |   Best Sellers   |   New Products   |   Deals & Specials   |   Under $10   |   SmartSavings Club

Trending News

Chronic Fatigue Syndrome, Fibromyalgia and Mitchondrial Disorders: A Comparison Plus the MitoQ Trial...

Myalgic encephalomyelitis, chronic fatigue syndrome: An infectious disease

Repair Damaged Mitochondria and Reduce Fatigue Up to 45%

Help Karina – Donate To Save4Children!

Misdiagnosis on a grand scale?

Are All the "Feel-Good" Pathways Blocked in Fibromyalgia and Chronic Fatigue Syndrome?

SURVEY RESULTS: Has Your Illness Affected What You Eat?

5 Things I've Learned About Chronic Illness Through Mindfulness

The Pressure We Put Ourselves Under To Find a Way Forward

Cellular Havoc: Zeroing In On The Sleep Problems in Fibromyalgia?

Print Page
Email Article

FDA Says Sponsors of Chronic Fatigue Syndrome Drugs can Rely on Patient-Reported Outcomes

  [ 16 votes ]   [ 1 Comment ]
By Alexander Gaffney • • March 18, 2014

FDA Says Sponsors of Chronic Fatigue Syndrome Drugs can Rely on Patient-Reported Outcomes
Note: You can read the FDA Guidance HERE.

RAPS Regulatory Focus Today 

Posted: 10 March 2014

By Alexander Gaffney, RAC

The US Food and Drug Administration (FDA) has released a new draft guidance document intended to expedite the development of drugs to treat chronic fatigue syndrome (also known as myalgic encephalomyelitis)—a poorly understood condition that has recently been subject to significant interest by FDA regulators.


Chronic fatigue syndrome (CFS) affects patients by causing severe, persistent and often debilitating fatigue. Little is known about the underlying causes of the condition, or even if it is a single condition or a group of related conditions. Despite numerous theories—including some that have since been discredited—there are no tests to determine its cause.

That leaves patients in something of a bind: The effects of CFS are real, but without an understanding of its underlying causes, researchers and manufacturers are unable to target potential or existing therapies to treat it.

That bind was put on display and amplified in February 2013, when FDA—following the advice of one of its advisory committee panels—did not recommend Hemispherx's Ampligen (rintalolimod), saying it needed additional clinical evidence and data before it could consider approving the drug.

But CFS patients are also the first to benefit from a special provision of the Food and Drug Administration Safety and Innovation Act (FDASIA), which calls for FDA to set up a "Patient-Focused Drug Development Initiative" to better take into account the views of patients during the regulatory review process.

"The human drug and biologic review process could benefit from a more systematic and expansive approach to obtaining input from patients who experience a particular disease or condition," FDA explained in a Federal Register posting announcing the program in September 2012.

In October 2012, FDA sat down with CFS patients in order to hear their views on the regulatory process, most notably including their tolerance for risk.

CFS Guidance

Now FDA is out with a new draft guidance document on how companies can develop drug products intended to treat CFS—a guidance that appears to take patient preference into account.
The guidance, Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: Developing Drug Products for Treatment, makes frequent note of the "unmet medical need" faced by CFS patients. That need means that CFS treatments will be eligible for special FDA regulatory designations, such as fast track designation, breakthrough therapy designation, accelerated approval and priority review status.

But it also addresses several difficult-to-answer questions. For example, how do you run a clinical trial on CFS patients when you have no idea if a person actually has CFS?

FDA's guidance has an answer: It's not entirely sure either.

"At this time, the FDA does not recognize any particular disease definition, nomenclature, or diagnostic criteria for CFS/ME as the most appropriate for use in clinical trials of new drug products," it wrote. However, it says that "any case definition or criteria" can be used by a sponsor to define a patient population. Those criteria or definitions will need to be justified to regulators, it said.

Patient-Reported Outcomes

As such, FDA also said it will be recommending some rather unique endpoints for CFS treatments. Efficacy endpoints "should include patient-reported symptoms using well-defined and reliable patient-reported outcome (PRO) instruments," FDA wrote.

"These patient-reported symptoms can include any scientifically supported and logical combination of symptoms that are common in CFS/ME," it added. Objective measures should also be considered, but are not necessarily required.

FDA said that "for most drug products, phase 3 trials that use a single primary efficacy endpoint with supportive secondary efficacy endpoints should be adequate to establish efficacy, provided the efficacy findings are robust and clinically meaningful."

The remainder of the guidance document goes into detail about specific efficacy trial considerations, such as trial design, efficacy endpoints, and trial duration.

FDA also said that in general, it will expect drug applications to be supported by two "definitive"—usually taken to mean Phase III—trials. Long-term safety data should also be collected, FDA wrote.

Comments on the guidance will be accepted by FDA through 10 May 2014.

Post a Comment

Featured Products From the ProHealth Store
Mitochondria Ignite™ with NT Factor® Ultra ATP+, Double Strength Hydroxocobalamin Extreme™

Looking for Vitamins, Herbs and Supplements?
Search the ProHealth Store for Hundreds of Natural Health Products

Article Comments Post a Comment

Half empty or half full?
Posted by: me/cfs
Mar 18, 2014
Which will most patients feel when reading this important change from the FDA, half empty or half full?

While it is good that the FDA will recognize patient reported outcomes (PRO) in future clinical trials, it is water under the bridge for Ampligen and its approval. On December 20, 2012, patient after patient made an extraordinary effort to express such reports to the FDA concerning Ampligen, only to have the FDA once again turn a deaf ear on February 4, 2013 when it rejected Ampligen for a second time.

It begs the question; Why did the cart come before the horse? Why didn't the FDA work with all interested parties to change the policy on PRO and then consider Ampligen's merits? The FDA owes it to all involved to open the case on Ampligen once again and base statistical analysis of past clinical trials in the light of this newly announced policy.
Reply Reply
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Subscribe Now!
Receive up-to-date ME/CFS, Fibromyalgia & Lyme Disease treatment and research news
 Privacy Guaranteed  |  View Archives

Repair Damaged Mitochondria and Reduce Fatigue Up to 45%

Featured Products

Hydroxocobalamin Extreme™ Hydroxocobalamin Extreme™
The B-12 your brain needs for detox & sharpness
MitoQ® MitoQ®
Powerful Antioxidant Support to Mitochondria
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Mitochondria Ignite™ with NT Factor® Mitochondria Ignite™ with NT Factor®
Reduce Fatigue up to 45%
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium

Natural Remedies

Nutrients to Combat the Modern Stress Epidemic Nutrients to Combat the Modern Stress Epidemic
Safely Burn Away Body Fat Safely Burn Away Body Fat
Anti-Inflammatory Properties of Tart Cherry Anti-Inflammatory Properties of Tart Cherry
Aches and Pains? A Simple Solution You'll Love Aches and Pains? A Simple Solution You'll Love
Green Coffee Extract: Unique Obesity Intervention Green Coffee Extract: Unique Obesity Intervention

What is Fibromyalgia?
Fibromyalgia Diagnosis
Fibromyalgia Symptoms
Fibromyalgia Causes
Fibromyalgia Treatments
Fibromyalgia Diet
Fibromyalgia Medications
M.E. & CFS
What is M.E./CFS?
M.E./CFS Diagnosis
M.E./CFS Symptoms
M.E./CFS Causes
M.E./CFS Treatments
M.E./CFS Diet
M.E./CFS Medications
What is Lyme Disease?
Lyme Disease Diagnosis
Lyme Disease Symptoms
Lyme Disease Causes
Lyme Disease Treatments
Lyme Disease Diet
Lyme Disease Medications
M.E. & CFS
Lyme Disease
General Health
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing